Pivotal clinical trials for new drugs have historically lacked racial and ethnic diversity. Over the past decade, the National Institutes of Health, the Food and Drug Administration, and private industry have invested to address this problem.

Oradores:: Sarah Thompson Schick

Tipo de evento: Seminario web

Fecha/hora de inicio:
10 January 2023, 2:00 PM ET
Fecha/hora de finalización:
10 January 2023, 3:00 PM ET

This has included guidance for sponsors, meetings, recommendations, and workshops. However, despite these attempts, most clinical trials do not recruit participants who accurately reflect the US population. This can lead to biased data and lack of trust in the approved medicine, and it reduces the value of the investment in clinical study.

AEI’s Kirsten Axelsen will host a panel of experts to discuss the root causes of the lack of clinical trial diversity, why it is important, and what policy changes could be made to achieve more accurate trial representation.


  • Marcella Alsan, Professor of Public Policy, Harvard Kennedy School
  • Sarah Thompson Schick, Life Sciences Regulatory and Compliance Lawyer
  • Susan C. Winckler, CEO, Reagan-Udall Foundation for the Food and Drug Administration